The contractor shall conduct studies that asses the role of metabolizing enzymes, transporters, and tissue permeability in the metabolism, transport, and distribution of dapivirine (DPV) in the…
Ended Awarded Last action
- Contract number
- 75N93018F00013
- Awardee
-
Advanced Bioscience Laboratories, Inc. UEI MK4QC9EKZXG8
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,426,173
Award facts
- Opportunity
-
- NIAIDDAIDSNIHAI2015029 Solicitation number
- Comprehensive Resources for HIV Microbicides and Biomedical Prevention Award Notice · Posted Jun 24, 2015
- Contract value 100% obligated
- $1,426,173.41 Current and potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541712 Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Rockville, MD 20850, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $6,109 | |
| Funding Only Action | $271,883 | |
| Funding Only Action | $229,002 | |
| Original award | $919,179 |
About this award
This is a cost-plus-fixed-fee contract awarded by the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases to Advanced Bioscience Laboratories, Inc. (ABL) to conduct studies assessing the role of metabolizing enzymes, transporters, and tissue permeability in the metabolism, transport, and distribution of dapivirine (DPV) in the lower female genital tract, and to explore the potential mechanisms for the DPV-miconazole interactions reported by the International Partnership for Microbicides. This contract has a potential value of $1,426,173.41 and a completion date of August 24, 2023. It was awarded on July 13, 2018 under the "HIV Microbicides and Biomedical Prevention 2016-2021" master IDIQ contract. The contract does not have a set-aside designation.
ABL is a contract research and manufacturing organization specializing in gene therapies, vaccines, oncolytics, and immunotherapies. The company has been awarded over $35 million in federal contracts to manufacture and test vaccine candidates, monoclonal antibodies, adjuvants, and other biologics for agencies including NIH and the Department of Health and Human Services.
Description
The contractor shall conduct studies that asses the role of metabolizing enzymes, transporters, and tissue permeability in the metabolism, transport, and distribution of dapivirine (DPV) in the lower female genital tract, and to explore the potential mechanisms for the DPV-miconazole interactions reported by the international partnership for microbicides (IPM) (aids research and human retroviruses, october 2014).
Quick answers
Who was awarded contract 75N93018F00013?
75N93018F00013 was awarded to Advanced Bioscience Laboratories, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on July 13, 2018.
How much is contract 75N93018F00013 worth?
The government has obligated $1,426,173 on 75N93018F00013.
Is contract 75N93018F00013 an order under another contract?
Yes. 75N93018F00013 is a delivery order under HHSN272201600008I, an indefinite delivery contract, on HIV Microbicides and Biomedical Prevention 2016-2021.
Was contract 75N93018F00013 competed?
The extent of competition for 75N93018F00013 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award